Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for OCUL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -2.581M
March 31, 2026 -0.294M
December 31, 2025 -449.38M
September 30, 2025 -10.36M
June 30, 2025 -97.81M
March 31, 2025 -4.183M
December 31, 2024 311.84M
September 30, 2024 -4.178M
June 30, 2024 -2.196M
March 31, 2024 -321.22M
December 31, 2023 -108.17M
September 30, 2023 -0.77M
June 30, 2023 -9.645M
March 31, 2023 -0.078M
December 31, 2022 -0.458M
September 30, 2022 -0.374M
June 30, 2022 -0.493M
March 31, 2022 -0.129M
December 31, 2021 -0.667M
September 30, 2021 -0.679M
June 30, 2021 -1.028M
March 31, 2021 -0.922M
December 31, 2020 -163.91M
September 30, 2020 -0.22M
June 30, 2020 -51.06M
Date Value
March 31, 2020 -12.82M
December 31, 2019 -9.091M
September 30, 2019 -18.61M
June 30, 2019 -5.408M
March 31, 2019 -4.955M
December 31, 2018 -5.839M
September 30, 2018 -12.92M
June 30, 2018 -8.254M
March 31, 2018 -35.26M
December 31, 2017 -1.206M
September 30, 2017 -1.726M
June 30, 2017 -0.993M
March 31, 2017 -26.27M
December 31, 2016 -0.823M
September 30, 2016 -0.078M
June 30, 2016 -0.198M
March 31, 2016 -0.005M
December 31, 2015 -0.133M
September 30, 2015 0.003M
June 30, 2015 -65.90M
March 31, 2015 -0.034M
December 31, 2014 -0.065M
September 30, 2014 -81.39M
June 30, 2014 -0.003M
March 31, 2014 -0.021M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
EyePoint, Inc. -20.18M
LENZ Therapeutics, Inc. -0.395M
Merck & Co., Inc. 714.00M
Theravance Biopharma, Inc. 0.967M
ANI Pharmaceuticals, Inc. 0.505M